Musings of a Prospective Angle Closure Patient
The “gold standard” treatment for angle closure disease is evolving – and it is a welcome change
Chelvin Sng | | Opinion
My interest in angle closure disease is both professional and personal. As an Asian woman with a strong family history of glaucoma – my mother had bilateral acute primary angle closure (APAC) and my father is a primary angle closure suspect (PACS) – irido-trabecular contact seems written into my genetic code. When I first embarked on my residency 15 years ago, laser peripheral iridotomy (LPI) was regarded as the “gold standard” treatment for angle closure disease, even in the absence of glaucoma or raised IOP (1). Surveys show that 84.9 percent of ophthalmologists in Singapore (2) and 75 percent in the United Kingdom would advise LPI for asymptomatic PACS (3).
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.